Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The US-based biotech shared the announcement as ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven ...

Based upon the rapid and deep reductions of total IgG observed with subcutaneous BHV-1300, Biohaven reiterates its plans to initiate a Phase 2 study in Graves' disease in mid-2025. Additional ...

Our ion channel platform expects to report topline pivotal results with our Kv7.2/7.3 potassium channel activator, BHV-7000, in major depressive disorder in 2H 2025 and in focal epilepsy in 1H 2026.